We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: orth America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
Generic name: Ciprofloxacin Lactate and Sodium Chloride Injection
English name: Ciprofloxacin Lactate Injection
Chinese Pinyin: Rusuan Huanbingshaxing Zhusheye
The main component of this product is: ciprofloxacin lactate, its chemical name is: 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3 -Quinoline carboxylic acid lactate.
Molecular formula: C17 H18FN3O3·C3H6O3
Molecular weight: 421.43
[Properties] This product is a colorless or almost colorless clear liquid.
Pharmacology and Toxicology
Pharmacological action: This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic gram-negative bacilli. It has a good antibacterial effect in vitro against the following bacteria: most bacteria of the Enterobacteriaceae, including Citrobacter spp. , Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It also has antibacterial activity against multi-drug resistant bacteria. The penicillin-resistant Neisseria gonorrhoeae, the enzyme-producing influenza Bacillus and Moraxella all have high antibacterial activity. It has antibacterial effect on most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, Streptococcus hemolyticus and Enterococcus faecalis. It has a good antimicrobial effect on Chlamydia trachomatis, Mycoplasma, Legionella, and has antibacterial activity on Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria.
Ciprofloxacin is a bactericide, which inhibits DNA synthesis and replication by acting on the A subunit of bacterial DNA helicase, leading to bacterial death.
Toxicological research:
Carcinogenicity and mutagenicity: 8 in vitro mutagenicity tests were performed on ciprofloxacin, and 2 of them were positive (rat hepatocyte DNA repair test and mouse lymphoma cell reversion test). However, in vivo tests of rat hepatocyte DNA repair test, micronucleus test (mice), and dominant test (mice) were all negative. Long-term carcinogenicity in vivo tests on rats and mice have been completed. After daily oral medication for 2 years, these animals did not show any carcinogenic or tumorigenic effects of ciprofloxacin.
Reproductive toxicity: Rats and mice were used to take 6 times the usual daily dose of humans for reproductive research. Ciprofloxacin has not been found to be harmful to the fetus or cause fertility damage. When ciprofloxacin is used in rabbits (30 and 100 mg/kg orally), gastrointestinal disturbances occur, leading to weight loss and increased miscarriage in female rabbits. However, no teratogenic effects were observed at the two doses. After intravenous administration of up to 20mg/kg, there was no maternal toxicity, embryo toxicity or teratogenicity. However, there are not enough, well-controlled studies on pregnant women. For pregnant women, ciprofloxacin can only be used when its potential benefits outweigh the potential risks to the fetus.
[Pharmacokinetics] After intravenous infusion of 200mg and 400mg of this product within 60 minutes, the blood drug depth peak is about 1 hour, respectively 2.1mg/L and 4.6mg/L. It can be widely distributed in various body fluids (including cerebrospinal fluid) and tissues, and the concentration in the tissues often exceeds the blood concentration. The protein binding rate is about 20%-40%. After intravenous administration, 50-70% of the drug is excreted in the urine in its original form, and about 14% is excreted in bile and feces. More than 90% of the dose is discharged within 24 hours. The elimination half-life is 5-6 hours, which can be prolonged by decreased renal function.
[Indications] Used for sensitive bacteria:
1. Urogenital system infections, including simple, complicated urinary tract infections, bacterial prostatitis, Neisseria gonorrhoeae urethritis or uterine
Cervical inflammation (including those caused by enzyme-producing strains).
2. Respiratory tract infections, including acute onset of bronchial infections and lung infections caused by sensitive gram-negative bacilli.
3. Gastrointestinal infections are caused by Shigella, Salmonella, Enterotoxigenic Escherichia coli, Hydrophilic Aeromonas, and Vibrio parahaemolyticus.
4. Typhoid fever.
5. Bone and joint infections.
6. Skin and soft tissue infections.
7. Systemic infections such as sepsis.
[Usage and Dosage] This product is for intravenous drip administration. For any patient, the dosage should be determined according to the degree and nature of the infection, the sensitivity of pathogenic bacteria, the patient's body resistance and liver and kidney function.
The general dosage for adults is 0.1-0.2g once, intravenously instilled once every 12 hours, and the infusion time of every 0.2g should be at least 30 minutes. For severe infection or Pseudomonas aeruginosa infection, the dose can be increased to 0.4g once a day 2-3 times.
The course of treatment depends on the degree of infection. Usually simple lower urinary tract infections are 5-7 days; complicated urinary tract infections are 7-14 days; pneumonia and skin and soft tissue infections: 7-14 days; intestinal infections: 5-7 days; bone and joint infections: 4-6 Weeks or longer; typhoid fever: 10-14 days.
Adverse reactions
1. Gastrointestinal reactions are more common and can be manifested as abdominal discomfort or pain, diarrhea, nausea or vomiting, indigestion, and anorexia. If you find severe long-term diarrhea during treatment, you must consult a doctor, because this may be a serious gastrointestinal disease, pseudomembranous enteritis. Once this happens, the drug should be stopped immediately. Give appropriate treatment (such as giving vancomycin). Drugs that inhibit gastrointestinal motility are prohibited.
2. Central nervous system reactions may include dizziness, headache, drowsiness or insomnia. A few cases may have abnormal peripheral pain, increased intracranial pressure, ataxia, convulsions, anxiety, confusion, depression, hallucinations, seizures, etc. Individual patients even have mental reaction and self-risk behavior. Some patients may have these reactions at the first time, so they should stop the medication immediately and notify the doctor.
3. Allergic reactions: skin rash, skin itching, drug fever, urticaria, and occasionally exudative erythema multiforme and angioedema may occur. In some cases, laryngeal edema, dyspnea, and anaphylactic shock may occur at the first medication, and anti-shock treatment should be given immediately. A few patients have photosensitivity.
4. Occasionally:
(1) Abnormal vision, impaired taste, tinnitus, and hearing loss.
(2) Hematuria, interstitial nephritis, hepatitis, and liver necrosis failure.
(3) Phlebitis or thrombophlebitis.
(4) Crystal urine is more common in high-dose applications.
(5) Joint pain, muscle pain, tenosynovitis, Achilles tendinitis;
(6) Tachycardia, facial flushing, migraine, syncope;
(7) Blood system effects: anemia, thrombocytopenia, leukopenia, eosinophilia, hemolytic anemia, coagulation changes. (8) Skin spotting (petechia) blisters, accompanied by bleeding (blood blisters) and crusted nodules (papules), stevens-Johnson and Yell syndrome.
(9) Long-term and repeated application of this product can cause infection by resistant bacteria or yeast-like bacteria.
5. Abnormal laboratory data: a small number of patients may have elevated serum aminotransferase, alkaline phosphatase, cholestatic jaundice, especially in patients with liver damage, blood urea nitrogen, creatinine or bilirubin increased, and individual patients have hyperglycemia and crystals Urine, hematuria.
6. Ciprofloxacin can affect the patient's ability to drive or operate machinery, especially in patients who drink at the same time.
[Contraindications] Patients who have a history of allergies to this product and any fluoroquinolones are contraindicated.
Audited Supplier
Pharma Sources Insight June 2024: Globalization on the Go
